426 related articles for article (PubMed ID: 20205482)
21. SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie N; Masoumi S; Alizadeh S; Mirzajanzadeh P; Nejabati HR; Hajiabbasi M; Alivirdiloo V; Basmenji NC; Derakhshi Radvar A; Majidi Z; Faridvand Y
Cell Biochem Funct; 2024 Jan; 42(1):e3922. PubMed ID: 38269506
[TBL] [Abstract][Full Text] [Related]
22. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Whaley JM; Tirmenstein M; Reilly TP; Poucher SM; Saye J; Parikh S; List JF
Diabetes Metab Syndr Obes; 2012; 5():135-48. PubMed ID: 22923998
[TBL] [Abstract][Full Text] [Related]
23. In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor.
Ganwir P; Bhadane R; Chaturbhuj GU
Comput Biol Chem; 2024 Jun; 110():108074. PubMed ID: 38678730
[TBL] [Abstract][Full Text] [Related]
24. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
Packer M; Wilcox CS; Testani JM
Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
[TBL] [Abstract][Full Text] [Related]
25. A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
Sokolov V; Yakovleva T; Stolbov L; Penland RC; Boulton D; Parkinson J; Tang W
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):831-841. PubMed ID: 36912425
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Chino Y; Samukawa Y; Sakai S; Nakai Y; Yamaguchi J; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2014 Oct; 35(7):391-404. PubMed ID: 25044127
[TBL] [Abstract][Full Text] [Related]
27. Epoxyeicosatrienoic acids improve glucose homeostasis by preventing NF-κB-mediated transcription of SGLT2 in renal tubular epithelial cells.
Fu M; Yu J; Chen Z; Tang Y; Dong R; Yang Y; Luo J; Hu S; Tu L; Xu X
Mol Cell Endocrinol; 2021 Mar; 523():111149. PubMed ID: 33387601
[TBL] [Abstract][Full Text] [Related]
28. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.
Hardman TC; Dubrey SW
Diabetes Ther; 2011 Sep; 2(3):133-45. PubMed ID: 22127823
[TBL] [Abstract][Full Text] [Related]
29. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Masuda T; Watanabe Y; Fukuda K; Watanabe M; Onishi A; Ohara K; Imai T; Koepsell H; Muto S; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F653-F664. PubMed ID: 29790389
[TBL] [Abstract][Full Text] [Related]
30. A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries.
Khine A; Lin E
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1707-1709. PubMed ID: 36323445
[No Abstract] [Full Text] [Related]
31. Exploring novel lead scaffolds for SGLT2 inhibitors: Insights from machine learning and molecular dynamics simulations.
Yu Y; Xia Y; Liang G
Int J Biol Macromol; 2024 Apr; 263(Pt 2):130375. PubMed ID: 38403210
[TBL] [Abstract][Full Text] [Related]
32. Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.
Gomez-Peralta F; Abreu C; Lecube A; Bellido D; Soto A; Morales C; Brito-Sanfiel M; Umpierrez G
Diabetes Ther; 2017 Oct; 8(5):953-962. PubMed ID: 28721687
[TBL] [Abstract][Full Text] [Related]
33. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus.
Bays H
Diabetes Ther; 2013 Dec; 4(2):195-220. PubMed ID: 24142577
[TBL] [Abstract][Full Text] [Related]
34. Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.
Poudel RR
Indian J Endocrinol Metab; 2013 Jul; 17(4):588-93. PubMed ID: 23961473
[TBL] [Abstract][Full Text] [Related]
35. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter.
Hiraizumi M; Akashi T; Murasaki K; Kishida H; Kumanomidou T; Torimoto N; Nureki O; Miyaguchi I
Nat Struct Mol Biol; 2024 Jan; 31(1):159-169. PubMed ID: 38057552
[TBL] [Abstract][Full Text] [Related]
36. SGLT2 inhibitor: 2-way superstar in nephrology?
Nangaku M
Kidney Int; 2024 Jun; 105(6):1176-1177. PubMed ID: 38777404
[No Abstract] [Full Text] [Related]
37. A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.
Niazi AK; Niazi SH
N Am J Med Sci; 2010 Dec; 2(12):556-60. PubMed ID: 22558567
[TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes.
Schaub JA; AlAkwaa FM; McCown PJ; Naik AS; Nair V; Eddy S; Menon R; Otto EA; Demeke D; Hartman J; Fermin D; O'Connor CL; Subramanian L; Bitzer M; Harned R; Ladd P; Pyle L; Pennathur S; Inoki K; Hodgin JB; Brosius FC; Nelson RG; Kretzler M; Bjornstad P
J Clin Invest; 2023 Mar; 133(5):. PubMed ID: 36637914
[TBL] [Abstract][Full Text] [Related]
39. Does it matter how we measure urinary creatinine in patients taking SGLT2 inhibitors?
Bock F; Isermann B
Nephrol Dial Transplant; 2024 Apr; 39(5):739-741. PubMed ID: 38218592
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
